ImmunoGen, Inc. Announces Presentations at Upcoming AACR Annual Meeting 2015

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the presentations on Company and partner programs to be made at the upcoming American Association for Cancer Research (AACR) annual meeting to be held April 18-22, 2015 in Philadelphia, PA. These presentations will feature scientific data for ImmunoGen and partner ADCs as well as an array of ImmunoGen technology innovations.

“The presentations on ADCs by ImmunoGen researchers and our partners at AACR this year illustrate our ongoing commitment to advancing the ADC field to achieve better therapies for people with cancer,” commented Daniel Junius, President and CEO. “The topics span research in support of our IMGN853 and IMGN779 product candidates, preclinical data for five partner ADCs, and some of the findings from our research related to site-specific payload attachment to antibodies.”

Presentations Related to ImmunoGen, Partner ADCs

- "Development and application of an immunohistochemistry-based clinical assay for evaluating Folate Receptor Alpha (FRα) expression in a phase I clinical trial of IMGN853." Abstract number: 4357
- "Plasma pharmacokinetics and tumor accumulation in mice of IMGN779, an antibody-drug conjugate for acute myeloid leukemia." Abstract number: 4504
- "In vitro and in vivo activity of a highly potent and novel FGFR2/FGFR4 dual targeting antibody-drug conjugate." Abstract number:1680
- "Development and activity of a novel antibody-drug conjugate for the treatment of P-cadherin expressing cancers." Abstract number: 1682
- "Generation of a novel maytansinoid-antibody-drug conjugate targeting LAMP1 expressed on the surface of tumor cells." Abstract number: 1689
- "Development of a novel antibody-drug conjugate for the treatment of c-Kit expressing solid tumors and AML." Abstract number: 1695
- "A c-Kit targeting antibody-drug conjugate is efficiently metabolized and activated inside cancer cell lines and xenograft tumors." Abstract number: 5325

Presentations by ImmunoGen Scientists on ADC Technology Innovations

Site-specific linkage; payload molecules/antibody - benefit assessment, novel approaches

- "Stability and efficacy comparison of site-specific and lysine-linked maytansinoid antibody-drug conjugates." Abstract number: 645
- "SeriMabs: N-terminal serine modification enables modular, site-specific payload incorporation into antibody-drug conjugates (ADCs)." Abstract number: 647
- "Antibody-drug conjugates: engineered N-terminal serine residues as a novel approach for site-specific conjugation." Abstract number: 653
- "Effects of drug load on therapeutic index for antibody-maytansinoid conjugates." Abstract number: 4531

Expanding portfolio of novel payload agents

- "Antibody-drug conjugates (ADCs) of indolino-benzodiazepine DNA-alkylating agents." Abstract number: 652

Advancing ADC screening methodologies

- "Microscale methods for preparation and screening of antibody-drug conjugates." Abstract number: 5442
About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's ADC technology uses tumor-targeting antibodies to deliver an ImmunoGen cell-killing agent specifically to cancer cells; the Company has also developed antibodies with anticancer activity of their own. The first product with ImmunoGen's ADC technology is Roche's Kadcyla®. ImmunoGen has three wholly owned product candidates in clinical testing with additional compounds in clinical testing through the Company's partnerships with Amgen, Bayer HealthCare, Biotest, Novartis and Sanofi. More information about ImmunoGen can be found at www.immunogen.com.

Kadcyla® is a registered trademark of Genentech, a member of the Roche Group.

This press release includes forward-looking statements. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. It should be noted that there are risks and uncertainties related to the development of novel anticancer products, including risks related to preclinical and clinical studies, their timings and results. A review of these risks can be found in ImmunoGen’s Annual Report on Form 10-K for the fiscal year ended June 30, 2014 and other reports filed with the Securities and Exchange Commission.

For Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
info@immunogen.com
or
For Media:
Pure Communications, Inc.
Dan Budwick, 973-271-6085

Source: ImmunoGen, Inc.

News Provided by Acquire Media